Vertex Pharmaceuticals (VRTX) has completed its acquisition of Crinetics Pharmaceuticals (CRNX), Vertex said on Tuesday.
Following the acquisition's closing, Jonathan Poole will take over Vertex's chief financial officer role, effective Jan. 1, Vertex said. Poole currently serves as Vertex's senior vice president for finance, the company said.
Charles Wagner, chief operating and financial officer of Vertex, will expand his COO role to head Crinetics' integration, effective immediately, Vertex said.
Price: 549.07, Change: +4.55, Percent Change: +0.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments